Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hyperuricemia

• PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
• Effect of Tigulixostat on the Pharmacokinetics of Theophylline
• Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
• Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
• Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
• A Phase 3 Study to Assess the Safety and Efficacy of 12 Months Treatment With Tigulixostat Compared to Allopurinol in Gout Patients With Hyperuricemia
• A Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment With Tigulixostat in Gout Patients With Hyperuricemia
• Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
• Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
• Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
• Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia
• Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
• A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
• A Phase I Clinical Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
• Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
• Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers
• Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
• Evaluation of Efficacy and Safety of AR882 in Gout Patients
• Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
• An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
• Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
• Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults
• Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
• A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
• Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
• Role of Uralyt-U in Patients With Hyperuricemia
• Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
• ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
• Probiotics for Gout / Hyperuricemia: Randomized, Double-blind, Intervention, Parallel Controlled, Multicenter
• A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
• Nutraceutical on Hyperuricemia
• The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
• Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.
• The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
• Mass Balance Study of [14C]LC350189 in Healthy Volunteers
• Renal PK Study of LC350189
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
• Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
• Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms
• A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
• A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
• The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
• D-0120 Safety and PK/PD Study in China
• Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
• Uric Acid Lowering Trial in Youth Onset T2D
• Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
• Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
• Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
• Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
• Effect of Hyperuricaemia on Chronic Renal Disease
• Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
• Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
• A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
• The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout
• Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level
• Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
• Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
• Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
• Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
• Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
• Gender Differences in the Metabolic Effects of Uric Acid
• Study of FYU-981 in Hyperuricemia With or Without Gout
• Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
• The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
• Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients
• The Effects of Rhus Coriaria L. on Serum Uric Acid Levels
• Multiple Dose Study of SHR4640 in Healthy Subjects
• Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
• Single Dose Study of SHR4640 in Healthy Subjects
• Zurig (Febuxostat) 40mg Efficacy and Safety Trial
• Study of URC102 to Assess the Safety and Efficacy in Gout Patients
• Pharmacogenetics of SGLT2 Inhibitors
• Study of FYU-981 in Hyperuricemia With or Without Gout
• Genetics of Hyperuricemia Therapy in Hmong
• Study of FYU-981 in Hyperuricemia With or Without Gout
• Compare the Renal Protective Effects of Febuxostat and Benzbromarone
• Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
• A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
• Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
• Long-term Prednisone Use for End-stage Heart Failure
• the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
• Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
• Phase II Exploratory Clinical Study of KUX-1151
• Prednisone for Heart Failure Patients With Hyperuricemia
• Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
• Effect of Allopurinol Treatment on Insulin Resistance
• Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy
• Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
• Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
• Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
• Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
• A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
• Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
• Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
• Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
• Hyperuricemia on Hypertension and Metabolic Syndrome
• Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
• Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
• Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
• Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
• Allopurinol in Chronic Heart Failure
• Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
• The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
• Gout Dose Response Study
• Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
• Prednisone for Heart Failure Patients With Hyperuricemia
• Lowering Serum Uric Acid to Prevent Acute Kidney Injury
• A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
• Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
• Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
• Rasburicase (Fasturtec) Registration Trial
• Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
• Treatment of Hyperuricemia in Patients With Heart Failure
• Rasburicase in Tumor Lysis Syndrome
• Rasburicase for Hyperuricemia
• Primary Prevention of Hypertension in Obese Adolescents
• Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
• Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
• A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
• Pharmacokinetic Study of Marine Active in Health Men
• Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
• Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients